Anything but Academic: Lessons From the PPAR Failures

Bristol and AstraZeneca lost major PPAR diabetes product development projects. Both companies got a nasty taste of a rapidly emerging force in the drug development process: the academic research organization. These academic centers are not shy about expressing their negative as well as positive opinions on drug development plans. Leading the pack is the Cleveland Clinic - the source of the safety questions that finished off the PPAR class.

Cole Werble

The pen is mightier than an FDA review—or at least it probably feels that way to PPAR drug developers.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet